Literature DB >> 17542369

Treatment of canine pediatric Neospora caninum myositis following immunohistochemical identification of tachyzoites in muscle biopsies.

Jennifer L Crookshanks1, Susan M Taylor, Deborah M Haines, G Diane Shelton.   

Abstract

A 7-week-old Irish wolfhound was evaluated for an abnormal hind limb gait. Quadriceps muscle atrophy was pronounced and patellar reflexes were absent bilaterally. Neospora caninum myositis was diagnosed by histopathologic and serologic examination and immunohistochemical staining of muscle. Substantial clinical improvement was noted after 18 weeks of treatment with clindamycin.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17542369      PMCID： PMC1852590     

Source DB:  PubMed          Journal:  Can Vet J        ISSN： 0008-5286            Impact factor:   1.008


  13 in total

Review 1.  Technical considerations for developing enzyme immunohistochemical staining procedures on formalin-fixed paraffin-embedded tissues for diagnostic pathology.

Authors:  D M Haines; B J Chelack
Journal:  J Vet Diagn Invest       Date:  1991-01       Impact factor: 1.279

2.  Detection of Neospora caninum tachyzoites in canine cerebrospinal fluid.

Authors:  Lluís Gaitero; Sònia Añor; Patrícia Montoliu; Angeles Zamora; Martí Pumarola
Journal:  J Vet Intern Med       Date:  2006 Mar-Apr       Impact factor: 3.333

Review 3.  Recent advances in Neospora and neosporosis.

Authors:  J P Dubey
Journal:  Vet Parasitol       Date:  1999-08-01       Impact factor: 2.738

4.  Clinical aspects of 27 cases of neosporosis in dogs.

Authors:  J S Barber; A J Trees
Journal:  Vet Rec       Date:  1996-11-02       Impact factor: 2.695

5.  Successful treatment of neosporosis in an adult dog.

Authors:  F M Thate; S C Laanen
Journal:  Vet Q       Date:  1998       Impact factor: 3.320

Review 6.  The comparative pathogenesis of neosporosis.

Authors:  David Buxton; Milton M McAllister; J P Dubey
Journal:  Trends Parasitol       Date:  2002-12

Review 7.  A review of Neospora caninum and neosporosis.

Authors:  J P Dubey; D S Lindsay
Journal:  Vet Parasitol       Date:  1996-12-02       Impact factor: 2.738

8.  Bovine neonatal encephalomyelitis associated with a Neospora sp. protozoan.

Authors:  L A Bryan; A A Gajadhar; J P Dubey; D M Haines
Journal:  Can Vet J       Date:  1994-02       Impact factor: 1.008

9.  Distribution of Neospora caninum within the central nervous system and other tissues of six dogs with clinical neosporosis.

Authors:  J S Barber; C E Payne-Johnson; A J Trees
Journal:  J Small Anim Pract       Date:  1996-12       Impact factor: 1.522

10.  Coyotes (Canis latrans) are definitive hosts of Neospora caninum.

Authors:  Luis F P Gondim; Milton M McAllister; William C Pitt; Doris E Zemlicka
Journal:  Int J Parasitol       Date:  2004-02       Impact factor: 3.981
View more
  4 in total

1.  Clinical features of idiopathic inflammatory polymyopathy in the Hungarian Vizsla.

Authors:  Anna Tauro; Diane Addicott; Rob D Foale; Chloe Bowman; Caroline Hahn; Sam Long; Jonathan Massey; Allison C Haley; Susan P Knowler; Michael J Day; Lorna J Kennedy; Clare Rusbridge
Journal:  BMC Vet Res       Date:  2015-04-21       Impact factor: 2.741

Review 2.  Canine neosporosis: perspectives on pathogenesis and management.

Authors:  Rodrigo C Silva; Gustavo P Machado
Journal:  Vet Med (Auckl)       Date:  2016-04-26

3.  Seroprevalence of Neospora caninum-specific antibodies in German breeding bitches.

Authors:  Rodolfo Villagra-Blanco; Lora Angelova; Theresa Conze; Gereon Schares; Andrea Bärwald; Anja Taubert; Carlos Hermosilla; Axel Wehrend
Journal:  Parasit Vectors       Date:  2018-02-17       Impact factor: 3.876

4.  Establishment of Novel High-Standard Chemiluminescent Assay for NTPase in Two Protozoans and Its High-Throughput Screening.

Authors:  Masamitsu Harada; Jun Nagai; Riho Kurata; Kenji Shimizu; Xiaofeng Cui; Takayuki Isagawa; Hiroaki Semba; Jun Ishihara; Yasuhiro Yoshida; Norihiko Takeda; Koji Maemura; Tomo Yonezawa
Journal:  Mar Drugs       Date:  2020-03-13       Impact factor: 5.118
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.